Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway
Head & Neck · 2026
DOI: 10.1002/hed.70165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Joo-Hwan Park und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Gachon University School of Medicine, Gil Medical Center, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Aminopyridines, Benzimidazoles, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF), Ministry of Health and Welfare, Republic of Korea, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background
HPV‐negative HNSCC is driven by cell cycle dysregulation, including CDK4/6 activation. Abemaciclib targets this pathway and may offer therapeutic benefits. This study aimed to identify biomarkers predicting abemaciclib efficacy.
Methods
In the NGS‐based TRIUMPH trial, patients with platinum‐refractory HNSCC harboring CDK4/6 pathway alteration received abemaciclib, classified as “long stable disease (SD)” (progression‐free survival [PFS] > 6 months) and “short SD” (PFS < 6 months). In this post hoc analysis, the genetic profiles were compared. In vitro studies were conducted to assess abemaciclib's antitumor effects in HNSCC cell lines.
Results
Among 23 patients, abemaciclib showed limited efficacy (overall response rate, 0%; disease control rate, 43.5%). CDKN2A deletion was significantly associated with long SD ( p = 0.0078), unlike CCND1 amplification and CDKN2A mutation. In vitro, CDKN2A ‐deleted cell lines showed greater sensitivity to abemaciclib.
Conclusions
Although abemaciclib resulted in limited tumor regression, CDKN2A deletion may be a predictive biomarker for prolonged disease stabilization. Further investigations on genomically selected populations and combination strategies are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Gachon University School of Medicine, Gil Medical Center, Incheon, Republic of Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
ORCID-Profile: Bhumsuk Keam, Hwan Jung Yun
Förderung
- National Research Foundation of Korea (NRF)
- Ministry of Health and Welfare, Republic of Korea
- Ministry of Health and Welfare
Zitieren
APA
Park, J. H., Ahn, H. K., Kim, H. R., Kim, S., Park, K. U., Yun, T., Kim, H. J., Lee, S. C., Cho, S. H., Park, S. G., Keam, B., & Yun, H. J. (2026). Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway. Head & Neck. https://doi.org/10.1002/hed.70165
Vancouver
Park JH, Ahn HK, Kim HR, Kim S, Park KU, Yun T, et al. Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway. Head & Neck. 2026. doi:10.1002/hed.70165
BibTeX
@article{Park2026,
author = {Park, Joo-Hwan and Ahn, Hee Kyung and Kim, Hye Ryun and Kim, Soyeon and Park, Keon-Uk and Yun, Tak and Kim, Hyo Jung and Lee, Sang-Cheol and Cho, Sang Hee and Park, Sang-Gon and Keam, Bhumsuk and Yun, Hwan Jung},
title = {Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70165}
}
EUVIMED